echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Apatinib, a heavyweight anticancer drug of Hengrui medicine, has been submitted to CFDA for signature and is expected to be approved within one month

    Apatinib, a heavyweight anticancer drug of Hengrui medicine, has been submitted to CFDA for signature and is expected to be approved within one month

    • Last Update: 2014-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: wisdom, September 29, 2014, great wisdom, ashdak news agency, September 29, 2014 According to the information on the website of CFDA, the review status of apatinib, a heavyweight new drug of Hengrui medicine (600276 SH), has been changed to "under approval", which means that the drug has been submitted to CFDA for signature According to the new drug review process, CFDA signature is the last administrative step, and apatinib is expected to be approved within one month According to the public data, apatinib belongs to class 1 chemical medicine It is a me better drug modified on the basis of vandetanib and PTK787, which is suitable for cancer patients after the failure of other treatment methods The preclinical research shows that its antitumor effect is better than that of PTK787 According to the information on CFDA website, apatinib is a major special drug At present, there are no domestic enterprises with the production approval documents of apatinib It is worth mentioning that the indication of apatinib for production is gastric cancer, and the indication of liver cancer is undergoing clinical trials at the same time Guangfa Securities research report pointed out that the annual incidence of gastric cancer in China is more than 500000, and the annual incidence of liver cancer is more than 400000 At present, the monthly average cost of TiNi patients is more than 10000 yuan, and the market space for gastric cancer and liver cancer indications is expected to reach 1 billion yuan (class C)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.